Galapagos (GLPG)

• Market cap: $1.91B
• 1 day: 0.8%
• 5 days: -0.21%
• 1 month: -8.65%
• 3 months: -15.29%
• 6 months: -8.57%
• Year to date: -11.62%
• 1 year: 16.19%
• 5 years: -64.65%
• 10 years: -36.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Employees: 452